In vitro the presence of P-glycoprotein is associated with the possibility to reverse multidrug resistance (MDR) with compounds with different structural features (Bradley et al., 1988). Although many such compounds have been described, only a few can be expected to be active at clinically achievable concentrations: quinidine (Tsuruo et al., 1984), amiodarone (Chauvet et al., 1987), bepridil (Schuurhuis et al., 1987) and cyclosporin A (Slater et al., 1986; Twentyman, 1988) are examples. During our investigations on the in vitro effects of resistance modifiers on daunorubicin and vincristine accumulation in freshly obtained human tumour cells (Schuurhuis et al., 1989b) we found that Cremophor EL, which is a polyethoxylated castor oil used as a solubiliser, e.g. of vitamins and of the immunosuppressant drug cyclosporin A, had effects on drug accumulation similar to other resistance modifiers used. In order to study whether this effect of Cremophor EL was related to MDR, we investigated the effects of Cremophor EL on anthracycline accumulation and anthracycline and vincristine cytotoxicity in MDR and sensitive model cell lines and we compared the results with those obtained using cyclosporin A and verapamil. Both human squamous lung cancer cells (SW-1573, Keizer et al., 1989; Broxterman et al., 1989) and human myeloma cells (8226, Dalton et al., 1986, 1989b) were used. The latter ones are of special interest because of the increased in vivo sensitivity of myeloma to a regimen containing vincristine, doxorubicin and dexamethasone (the VAD regimen) when verapamil is used as a modifier (Dalton et al., 1989a). Both types of MDR cells overexpress P-glycoprotein (Dalton et al., 1989b; Kuiper et al., 1990).

Cells were cultured in Dulbecco's modified minimal essential medium supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland). The human multiple myeloma 8226Dox4 and 8226Dox40 cells were cultured in the presence of 40 and 400 nM doxorubicin (Adriablastina, Farmitalia, Milan, Italy) respectively. SW-1573/2R160 cells were derived from SW-1573/2R50 cells (Keizer et al., 1989; Broxterman et al., 1989) by continuous exposure to 160 nM doxorubicin. Experiments were performed on cells cultured for 1–2 weeks without doxorubicin. Cells were allowed to adhere (SW-1573 cells) or equilibrate in suspension (8226 cells) in six-well tissue culture plates (Costar, Cambridge, MA, USA). Then they were incubated under 5% CO₂, with doxorubicin or vincristine sulfate (Sigma Chemical Co, St Louis, MO, USA) with or without resistance modifiers for at least three cell doubling times. Cell doubling times were 22 h (SW-1573), 45 h (SW-1573/2R160), 36 h (8226S), 42 h (8226Dox4) and 44 h (8226Dox40). Thereafter the cells were counted as described by Schuurhuis et al. (1987) using a Sigmex microcell counter model CC-110. With high concentrations of Cremophor EL (> 132 μg ml⁻¹) or when fresh human plasma was used, the cells were co-incubated with doxorubicin and Cremophor EL for 2 h, post-incubated for 2 h with Cremophor EL only and further incubated in fresh medium as described above. Resistance modifiers used were verapamil·HCl (Sigma), cyclosporin A (Sandoz AG, Basel, Switzerland), cyclosporin A in Cremophor EL (Sandimmune, Sandoz, AG) and Cremophor EL (Sandoz AG). Cyclosporin A in Cremophor EL was used because in this form (Sandimmune) cyclosporin A is administered clinically. The choice of the concentration of the modifiers used in the cytotoxicity experiments in this study is based on other in vitro studies: 2 μM cyclosporin A and 4 μM verapamil usually are effective in modulating MDR (Durie & Dalton, 1988; further reviewed in Twentyman, 1988 and Kaye, 1988). The choice of Cremophor EL concentrations is based on the amounts present in the cyclosporin A solutions which are administered in the clinic (Sandimmune), e.g. a final dilution of 2 μM cyclosporin A contains 33 μg ml⁻¹ Cremophor EL.

Cellular accumulation and efflux experiments were performed essentially as described earlier (Schuurhuis et al., 1987). Some 0.1–0.3 × 10⁶ cells were incubated for 2 h at 37°C in 550 μl Dulbecco's medium, pH 7.4, lacking NaHCO₃ but containing 20 mM HEPES and 10% fetal bovine serum, to which ²²Na-doxorubicin (Amersham Laboratories, Amersham, UK) or ¹⁴C-daunorubicin (Amer sham) was added with or without resistance modifiers. The final concentration of doxorubicin and daunorubicin was made 0.5 μM by adding unlabelled doxorubicin and daunorubicin (Specia, Paris, France). After two washes with ice-cold phosphate-buffered saline, the cells were transferred to liquid scintillation fluid. No corrections were made for direct binding of anthracyclines to the cells since binding was the same whether or not modifiers were present and was too low to affect the conclusions (5–20% at maximum). For efflux experiments sensitive cells were incubated with 0.5 μM doxorubicin or daunorubicin. Resistant cells were incubated with 2.5 μM daunorubicin (SW-1573/2R160) or 1 μM doxorubicin (8226Dox4); this resulted in about the same intracellular drug amounts as in the sensitive cells in these experiments after 2 h of incubation. After washing with ice-cold Dulbecco's medium, the cells were resuspended in fresh ice-cold medium and incubated for 1 h at 37°C. After washing the cell-associated radioactivity was determined.

In Table I it is shown that Cremophor EL (132 μg ml⁻¹) partly reversed doxorubicin resistance in SW-1573/2R160 cells (the dose modifying factor, DMF, was 6.3; resistance index = 77) while only a small effect was observed on the parent cell line. With concentrations higher than 132 μg ml⁻¹ higher dose modifying factors were found (see Table I). At a concentration of 33 μg ml⁻¹ Cremophor EL had a small although significant effect in SW-1573/2R160 cells (DMF = 1.9, see Table I). Two μM pure cyclosporin A had a DMF of 8.3 ± 1.5 (mean ± s.d. in three experiments, P < 0.01), while 2 μM cyclosporin A (Sandimmune), which

Correspondence: G.J. Schuurhuis.
Received 8 January 1990; and in revised form 17 April 1990.
contains 33 μg ml\(^{-1}\) Cremophor EL, had a DMF of 16.8 (Table I). These results show that both compounds as such are able to sensitize SW-1573/2R160 cells to doxorubicin and that the effects are additive when cyclosporin A is given as Sandimmune.

Also in the human myeloma cell line 8226Dox4 with a moderately high doxorubicin resistance index (45, see Table I) Cremophor EL (33 μg ml\(^{-1}\)) had only a small effect (DMF of 2.6, see Table I). Like in SW-1573/2R160 cells, with higher concentrations of Cremophor EL the effects on doxorubicin cytotoxicity became more pronounced (Table I). On the other hand, in 8226Dox4 cells with a low doxorubicin resistance index (7.9, see Table I) 33 μg ml\(^{-1}\) Cremophor EL largely reversed doxorubicin resistance (Table I and Figure 1). One μM cyclosporin A in Cremophor EL (16.5 μg ml\(^{-1}\)) or verapamil (4 or 16 μM) had no greater effect than Cremophor EL (33 μg ml\(^{-1}\)) alone (Table I). Figure 1 shows the dose – response relationship for Cremophor EL on doxorubicin cytotoxicity: even at concentrations of 4.1 and 8.2 μg ml\(^{-1}\) (which correspond to dilutions of 1:256,000 and 1:128,000 respectively), significant effects were observed. These data show that in cells with low levels of MDR reversal of resistance with cyclosporin A may have been achieved at least partly due to the carrier (Cremophor EL) effects alone. This may have important implications for the design and interpretation of clinical trials with cyclosporin A as reversing agent.

Interestingly, our results indicate that cells with intermediate to high levels of resistance, like 8226Dox4 and SW-1573/2R160 cells, may not be good models to predict the possible clinical usefulness of resistance modifiers in P-glycoprotein-containing tumours. This may be due to the fact that drug efflux from cells with low amounts of P-glycoprotein can be blocked more efficiently.

Drug accumulation experiments confirmed the findings reported above. Cremophor EL significantly stimulated doxorubicin and daunorubicin accumulation in 8226Dox4 and SW-1573/2R160 cells, respectively, but not in the sensitive cells (Table II). In SW-1573/2R160 cells daunorubicin was used instead of doxorubicin, since drug accumulation differences between sensitive and resistant cells and importantly, effects of modifiers on drug accumulation in resistant cells, were much more pronounced for daunorubicin than for doxorubicin in these cells. Cremophor EL (132 μg ml\(^{-1}\)) stimulates anthracycline accumulation at least partly by in-

### Table I
Effect of resistance modifiers on doxorubicin cytotoxicity in human squamous lung cancer and myeloma MDR and sensitive cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>IC(_50) (nM)</th>
<th>CEL (33 μg ml(^{-1}))</th>
<th>CEL (132 μg ml(^{-1}))</th>
<th>Cycl. A</th>
<th>V(_p) (4 μM)</th>
<th>V(_p) (16 μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SW-1573</td>
<td>22 ± 5</td>
<td>1.6 ± 0.4*</td>
<td>1.8 ± 0.6</td>
<td>1.4 ± 0.2</td>
<td>1.5 ± 0.1</td>
<td></td>
</tr>
<tr>
<td>SW-1573/2R160</td>
<td>1700 ± 300 [77]</td>
<td>1.9 ± 0.1*</td>
<td>6.3 ± 0.1*</td>
<td>16.8 ± 6.1*</td>
<td>5.4 ± 0.5*</td>
<td>11.0 ± 1.4*</td>
</tr>
<tr>
<td>8226S</td>
<td>12 ± 2</td>
<td>1.2 ± 0.1</td>
<td>1.1 ± 0.3</td>
<td>1.1 ± 0.1</td>
<td>1.4 ± 0*</td>
<td></td>
</tr>
<tr>
<td>8226Dox4</td>
<td>95 ± 12 [7.9]</td>
<td>5.4 ± 1.7</td>
<td>7.1 ± 1.2</td>
<td>4.6 ± 0.2*</td>
<td>3.4 ± 0.3*</td>
<td>4.9 ± 0.8*</td>
</tr>
<tr>
<td>8226Dox40</td>
<td>540 ± 110 [45]</td>
<td>2.6 ± 1.3</td>
<td>13.3 ± 2.8</td>
<td>5.6 ± 2.2*</td>
<td>8.4 ± 2.7*</td>
<td></td>
</tr>
</tbody>
</table>

\(\text{IC}_{50}\): IC\(_50\) (control) values. CEL: Cytotoxic effect (IC\(_50\) concentration in medium). DMF: dose modifying factor = IC\(_50\) without resistance modifier/IC\(_50\) with resistance modifier.

### Table II
Effect of resistance modifiers on anthracycline accumulation and retention in human squamous lung cancer and myeloma MDR and sensitive cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>anthracycline accumulation (pmol per 10(^6) cells)</th>
<th>CEL (132 μg ml(^{-1}))</th>
<th>Cycl. A (8 μM)</th>
<th>V(_p) (16 μM)</th>
<th>Anthr. retention</th>
<th>REF*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SW-1573</td>
<td>346 ± 52</td>
<td>0.99 ± 0.08*</td>
<td>1.05 ± 0.12</td>
<td>1.18 ± 0.11*</td>
<td>63 ± 12*</td>
<td>1.12 ± 0.17</td>
</tr>
<tr>
<td>SW-1573/2R160</td>
<td>56 ± 8 [6.2]</td>
<td>2.05 ± 0.39*</td>
<td>4.39 ± 0.88*</td>
<td>3.09 ± 0.45*</td>
<td>34 ± 8</td>
<td>1.37 ± 0.09*</td>
</tr>
<tr>
<td>8226S</td>
<td>147 ± 17</td>
<td>0.94 ± 0.19</td>
<td>1.05 ± 0.18</td>
<td>0.99 ± 0.11</td>
<td>72 ± 5</td>
<td>0.98 ± 0.04*</td>
</tr>
<tr>
<td>8226Dox4</td>
<td>107 ± 20 [1.4]</td>
<td>1.24 ± 0.11*</td>
<td>1.34 ± 0.16*</td>
<td>1.30 ± 0.19*</td>
<td>67 ± 9</td>
<td>1.08 ± 0.05*</td>
</tr>
<tr>
<td>8226Dox40</td>
<td>84 ± 1 [1.8]</td>
<td>1.27 ± 0.17*</td>
<td>1.54 ± 0.26*</td>
<td>1.30 ± 0.18*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations as in Table I. *Drug accumulation (2 h at 37°C) was carried out with 0.5 μM daunorubicin for SW-1573 cells and with 0.5 μM doxorubicin for 8226 cells. **AEF, accumulation enhancement factor = drug accumulation with modifier/drug accumulation without modifier.\(^*\) Anthracycline retention was measured after 1 h of drug efflux; shown are means (± s.d.) of initial amounts. **REF, retention enhancement factor = drug retention with CEL (132 μg ml\(^{-1}\))/drug retention without CEL. **Values are means ± s.d. from 2–3 independent experiments each performed in triplicate. **Values between brackets: drug accumulation in sensitive cells/drug accumulation in resistant cells. **Significantly different from 1 (P < 0.05, Student’s t test). **Significantly different from 1 (P < 0.01).
creasing its retention in the MDR cells (Table II), as seems to be the case for cyclosporin A (Nooter et al., 1989). No significant effects of Cremophor EL on anthracycline retention were seen in the parent cells. The effects of the modifiers on drug cytotoxicity in MDR cells seems to be due for an important part to a change in intracellular drug distribution instead of to stimulation of drug accumulation as will be discussed later. In addition, stimulation of anthracycline accumulation by modifiers occurs in a dose-dependent way and therefore low concentrations of modifiers stimulate anthracycline accumulation only slightly. In order to show clearly that the resistance modifiers used stimulate drug accumulation in our MDR cells we have chosen higher concentrations of modifiers for accumulation and retention experiments than for cytotoxicity experiments.

We have also determined the effect of Cremophor EL on vincristine cytotoxicity in 8226Dox4 cells since vincristine is included in clinical protocols for myeloma patients. Figure 2 shows that Cremophor EL is active in reversing vincristine resistance with dose modifying factors of 2.2, 3.2, 8.4 and 28.7 for the concentrations of 8.2, 16.5, 33 and 132 μg mL⁻¹, respectively. Since the resistance index was 15, this means a more than complete reversal of resistance at 132 μg mL⁻¹.

Interestingly, the sensitive cells were affected too, although to a limited extent (DMF: 2.2, see Figure 2). Two μM verapamil, a concentration which is only achievable clinically with serious side-effects (Benson et al., 1985; Ozols et al., 1987) was less effective than Cremophor EL at a concentration of 33 μg mL⁻¹ (see Figure 2).

One major determinant of the efficacy of a drug in the clinic can be its ability to bind to proteins (Koch-Weser & Sellers, 1976). We have shown previously that an increase in the protein concentration significantly decreased the potency of resistance modifiers such as verapamil, bepridil, diltiazem and Ro 11–2933/001 to stimulate anthracycline accumulation in MDR cells (Broxterman et al., 1987). Table III shows that Cremophor EL at concentrations of 33 and 132 μg mL⁻¹ largely retains its ability to reverse doxorubicin resistance in 8226Dox4 cells at a high protein concentration (compare Tables I and III). At this protein concentration the dose modifying factors of verapamil, even at a concentration of 16 μM, are somewhat lower than for Cremophor EL (Table III). In addition, when 8226Dox4 cells were incubated in fresh human plasma for 2 h with doxorubicin and Cremophor EL (132 μg mL⁻¹), followed by a 2 h post-incubation in plasma with Cremophor EL only, the effect was about the same as in control experiments using 10% fetal bovine serum in the same incubation protocol (DMF of 2.5–3.5). These results indicate that proteins probably do not strongly interfere with the capacity of Cremophor EL to modulate MDR.

Despite the many studies addressing the mechanism of action of resistance modifiers, the answers offered are not yet satisfactory. Resistance modifiers seem to act at least partly by binding to P-glycoprotein (Safa et al., 1986; Cornell et al., 1986; Foxwell et al., 1987) and competing for drug efflux via P-glycoprotein (Bradley et al., 1988), thereby increasing drug accumulation in the cell. As an alternative some resistance modifiers may act via their detergent effect on membranes as reported for Tween 80 (Carlson et al., 1976). We have shown previously that the action of resistance modifiers may be due largely to their effects on the intracellular drug localisation instead of on drug accumulation: in cells with high levels of MDR doxorubicin is present mainly in the cytoplasm in the absence of resistance modifiers. However, in the presence of resistance modifiers doxorubicin is mainly in the nucleus, as is the situation in drug-sensitive cells (Williams et al., 1986; Schuurhuis et al., 1989a; Broxterman et al., 1990). Cremophor EL also was able to produce a similar change in drug localisation (from mainly cytoplasmic to mainly nuclear) in SW-1573/2R160 cells as determined with fluorescence microscopy (results not shown). These observations offer an explanation for the finding that modifiers such as cyclosporin A are able to reverse drug resistance to a large extent without strongly affecting drug accumulation (Slater et al., 1986; Schuurhuis et al., 1989a; this study).

Since protein kinase C (PKC) activity has been associated with MDR and its reversal (Aquin et al., 1988; Fine et al., 1988; O’Brien et al., 1988; Ferguson & Cheng, 1987), it is of interest that Cremophor EL, like other resistance modifiers such as verapamil, tamoxifen, cyclosporin A and phenothiazines (Mori et al., 1980; O’Brien et al., 1985; Walker et al., 1989; Schatzlein et al., 1981), strongly inhibits PKC activity at concentrations comparable to those used in this study (Zhao et al., 1989).

In conclusion, our findings demonstrate that Cremophor EL is a potent modifier of MDR in human myeloma cells at protein concentrations which closely mimic the in vivo situation. Clinical studies in myeloma with Cremophor EL as a resistance modifier thus seem warranted. Further, Cremophor

---

**Table III** Reversal of doxorubicin resistance in 8226 MDR cells in protein-rich medium

<table>
<thead>
<tr>
<th>Cell line</th>
<th>IC₅₀ (μM) (control)</th>
<th>CEL (33 μg mL⁻¹)</th>
<th>CEL (132 μg mL⁻¹)</th>
<th>Vp 4 μM</th>
<th>Vp 16 μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>8226S</td>
<td>26.3 ± 5.9</td>
<td>1.0 ± 0.1</td>
<td>12.2 ± 0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8226Dox4</td>
<td>250 ± 71 (9.5)</td>
<td>5.5 ± 0.7</td>
<td>2.0 ± 0.7</td>
<td>3.5 ± 0.7</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations as in Table I. *The growth medium contained 4% bovine serum albumin (Sigma) in addition to 10% fetal calf serum. **DMF: dose modifying factor: IC₅₀ minus resistance modifier/IC₅₀ plus resistance modifier. *Values are means ± s.d. from 2–3 experiments. •Values between brackets: IC₅₀, 8226Dox4 cells/IC₅₀, 8226S cells.

Significantly different from 1 (P < 0.05, Student’s t test). Significantly different from 1 (P < 0.02).
This work was supported by grants from the Netherlands Cancer Foundation (KCA VU 88-22) and from the Bristol-Myers Squibb Company. We thank Dr W.S. Dalton (Tucson, Arizona) for supplying the 8226 myeloma cells and Dr H. Joene (Amsterdam, The Netherlands) for his gift of the SW-1573 and the SW-1573/2R50 cells, from which the SW-1573/2R160 cells used in this study were derived.


